These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30405615)

  • 41. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High beta-chemokine expression levels in lymphoid tissues of simian/human immunodeficiency virus 89.6-vaccinated rhesus macaques are associated with uncontrolled replication of simian immunodeficiency virus challenge inoculum.
    LaFranco-Scheuch L; Abel K; Makori N; Rothaeusler K; Miller CJ
    J Virol; 2004 Jun; 78(12):6399-408. PubMed ID: 15163733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
    Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
    AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Replication, immunogenicity, and protective properties of live-attenuated simian immunodeficiency viruses expressing interleukin-4 or interferon-gamma.
    Stahl-Hennig C; Gundlach BR; Dittmer U; ten Haaft P; Heeney J; Zou W; Emilie D; Sopper S; Uberla K
    Virology; 2003 Jan; 305(2):473-85. PubMed ID: 12573592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Protective immune responses against HIV/SIV by live attenuated vaccine in non-human primate models].
    Fukazawa Y
    Uirusu; 2012; 62(2):167-74. PubMed ID: 24153227
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection.
    Lynch RM; Yamamoto T; McDermott AB
    Curr Opin HIV AIDS; 2013 Jul; 8(4):288-94. PubMed ID: 23666390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV vaccine development: lessons from the past and promise for the future.
    Spearman P
    Curr HIV Res; 2003 Jan; 1(1):101-20. PubMed ID: 15043215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonhuman primate models for HIV/AIDS vaccine development.
    Sui Y; Gordon S; Franchini G; Berzofsky JA
    Curr Protoc Immunol; 2013 Oct; 102():12.14.1-12.14.30. PubMed ID: 24510515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rapid, repeated, low-dose challenges with SIVmac239 infect animals in a condensed challenge window.
    Greene JM; Weiler AM; Reynolds MR; Cain BT; Pham NH; Ericsen AJ; Peterson EJ; Crosno K; Brunner K; Friedrich TC; O'Connor DH
    Retrovirology; 2014 Aug; 11():66. PubMed ID: 25125288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mucosal Humoral Immune Response to SIVmac239∆nef Vaccination and Vaginal Challenge.
    Zeng M; Smith AJ; Shang L; Wietgrefe SW; Voss JE; Carlis JV; Li Q; Piatak M; Lifson JD; Johnson RP; Haase AT
    J Immunol; 2016 Mar; 196(6):2809-18. PubMed ID: 26864031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines.
    Staprans SI; Feinberg MB
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S5-32. PubMed ID: 15285703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.
    Lifson JD; Haigwood NL
    Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a007310. PubMed ID: 22675663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade.
    Vaccari M; Boasso A; Fenizia C; Fuchs D; Hryniewicz A; Morgan T; Weiss D; Doster MN; Heraud JM; Shearer GM; Franchini G
    J Virol; 2012 Jan; 86(1):108-13. PubMed ID: 22013040
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques.
    Dyavar Shetty R; Velu V; Titanji K; Bosinger SE; Freeman GJ; Silvestri G; Amara RR
    J Clin Invest; 2012 May; 122(5):1712-6. PubMed ID: 22523065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current advances in HIV vaccine preclinical studies using Macaque models.
    Liang B; Li H; Li L; Omange RW; Hai Y; Luo M
    Vaccine; 2019 Jun; 37(26):3388-3399. PubMed ID: 31088747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8
    Rahman SA; Yagnik B; Bally AP; Morrow KN; Wang S; Vanderford TH; Freeman GJ; Ahmed R; Amara RR
    Sci Immunol; 2021 Sep; 6(63):eabh3034. PubMed ID: 34516743
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical AIDS vaccine development: formal survey of global HIV, SIV, and SHIV in vivo challenge studies in vaccinated nonhuman primates.
    Warren JT; Levinson MA
    J Med Primatol; 1997; 26(1-2):63-81. PubMed ID: 9271191
    [No Abstract]   [Full Text] [Related]  

  • 59. Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.
    Ackerman ME; Das J; Pittala S; Broge T; Linde C; Suscovich TJ; Brown EP; Bradley T; Natarajan H; Lin S; Sassic JK; O'Keefe S; Mehta N; Goodman D; Sips M; Weiner JA; Tomaras GD; Haynes BF; Lauffenburger DA; Bailey-Kellogg C; Roederer M; Alter G
    Nat Med; 2018 Oct; 24(10):1590-1598. PubMed ID: 30177821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).
    Gill AL; Green SA; Abdullah S; Le Saout C; Pittaluga S; Chen H; Turnier R; Lifson J; Godin S; Qin J; Sneller MC; Cuillerot JM; Sabzevari H; Lane HC; Catalfamo M
    AIDS; 2016 Oct; 30(16):2487-2493. PubMed ID: 27490642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.